Actinium Pharmaceuticals Files Q1 2024 10-Q

TL;DR

**ATNM filed its Q1 10-Q, check compliance and reporting status.**

AI Summary

Actinium Pharmaceuticals, Inc. filed its quarterly report for the period ended March 31, 2024. The company is registered in Delaware and its common stock trades under the symbol ATNM on the NYSE American exchange. The filing indicates whether the company has met its reporting requirements for the preceding 12 months and the past 90 days.

Why It Matters

This filing provides an update on Actinium Pharmaceuticals' financial and operational status, crucial for investors to assess the company's performance and compliance.

Risk Assessment

Risk Level: low — This is a routine quarterly filing and does not contain new material events or financial disclosures that would inherently increase risk.

Key Players & Entities

• Actinium Pharmaceuticals, Inc. (company) — Registrant
• March 31, 2024 (date) — Quarterly period ended
• ATNM (company) — Trading Symbol
• NYSE American (company) — Exchange

FAQ

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 ATNM NYSE American Indicate by check

Filing Documents

• ea0203758-10q_actinium.htm (10-Q) — 781KB
• ea020375801ex31-1_actinium.htm (EX-31.1) — 10KB
• ea020375801ex31-2_actinium.htm (EX-31.2) — 10KB
• ea020375801ex32-1_actinium.htm (EX-32.1) — 3KB
• ea020375801ex32-2_actinium.htm (EX-32.2) — 4KB
• image_001.jpg (GRAPHIC) — 684KB
• image_002.jpg (GRAPHIC) — 16KB
• image_003.jpg (GRAPHIC) — 611KB
• image_004.jpg (GRAPHIC) — 521KB
• image_005.jpg (GRAPHIC) — 204KB
• image_006.jpg (GRAPHIC) — 684KB
• image_007.jpg (GRAPHIC) — 15KB
• image_008.jpg (GRAPHIC) — 20KB
• image_009.jpg (GRAPHIC) — 20KB
• image_010.jpg (GRAPHIC) — 206KB
• image_011.jpg (GRAPHIC) — 23KB
• image_012.jpg (GRAPHIC) — 14KB
• image_013.jpg (GRAPHIC) — 17KB
• image_014.jpg (GRAPHIC) — 21KB
• image_015.jpg (GRAPHIC) — 25KB
• 0001213900-24-036699.txt ( ) — 10875KB
• atnm-20240331.xsd (EX-101.SCH) — 33KB
• atnm-20240331_cal.xml (EX-101.CAL) — 27KB
• atnm-20240331_def.xml (EX-101.DEF) — 154KB
• atnm-20240331_lab.xml (EX-101.LAB) — 305KB
• atnm-20240331_pre.xml (EX-101.PRE) — 150KB
• ea0203758-10q_actinium_htm.xml (XML) — 252KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 42 Item 4.

Controls and Procedures

Controls and Procedures 42

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 43 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 75 Item 3. Defaults Upon Senior Securities 75 Item 4. Mine Safety Disclosures 75 Item 5. Other Information 75 Item 6. Exhibits 76

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS The accompanying consolidated financial statements have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position at March 31, 2024 and December 31, 2023, and the results of operations and cash flows for the three months ended March 31, 2024 and 2023, respectively, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company's audited financial statements for the year ended December 31, 2023 in the Company's Annual Report on Form 10-K. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the operating results for the full year. 1 Actinium Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (Unaudited) (amounts in thousands, except share and per share data) March 31, 2024 December 31, 2023 (Unaudited) Assets Current Assets: Cash and cash equivalents $ 84,057 $ 76,677 Prepaid expenses and other current assets 1,316 1,586 Total Current Assets 85,373 78,263 Property and equipment, net of accumulated depreciation of $ 760 and $ 694 496 550 Restricted cash – long term 316 313 Operating leases right-of-use assets 2,140 2,289 Finance leases right-of-use assets 27 30 Total Assets $ 88,352 $ 81,445 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable and accrued expenses $ 7,513 $ 7,953 Operating leases current liability 540 530 Finance leases current liability 11 11 Total Current Liabilities 8,064 8,494 Long-term license revenue deferred 35,000 35,0

financial statements

financial statements. 2 Actinium Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) (amounts in thousands, except share and per share data) For the Three Months Ended March 31 2024 2023 Revenue: Revenue $ - $ - Other revenue - - Total revenue - - Operating expenses: Research and development, net of reimbursements 6,635 7,849 General and administrative 2,962 3,735 Total operating expenses 9,597 11,584 Loss from operations ( 9,597 ) ( 11,584 ) Other income: Interest income - net 927 547 Total other income 927 547 Net loss $ ( 8,670 ) $ ( 11,037 ) Net loss per share of common stock – basic and diluted $ ( 0.31 ) $ ( 0.43 ) Weighted average shares of common stock outstanding – basic and diluted 27,886,486 25,696,623 See accompanying notes to the condensed consolidated

financial statements

financial statements. 3 Actinium Pharmaceuticals, Inc. Condensed Consolidated Statement of Changes in Stockholders' Equity For the Period from January 1, 2024 to March 31, 2024 (Unaudited) (amounts in thousands, except share amounts) Common Stock Additional Paid-In Accumulated Stockholders' Shares Amount Capital Deficit Equity Balance, January 1, 2024 27,634,213 $ 28 $ 373,934 $ ( 337,583 ) $ 36,379 Stock-based compensation - - 1,378 - 1,378 Sale of common stock, net of offering costs 1,752,050 1 14,694 - 14,695 Issuance of common stock from exercise of stock options 10,148 - 75 - 75 Net loss - - - ( 8,670 ) ( 8,670 ) Balance, March 31, 2024 29,396,411 $ 29 $ 390,081 $ ( 346,253 ) $ 43,857 See accompanying notes to the condensed consolidated

financial statements

financial statements. 4 Actinium Pharmaceuticals, Inc. Condensed Consolidated Statement of Changes in Stockholders' Equity For the Period from January 1, 2023 to March 31, 2023 (Unaudited) (amounts in thousands, except share amounts) Common Stock Additional Paid-In Accumulated Stockholders' Shares Amount Capital Deficit Equity Balance, January 1, 2023 25,674,823 $ 26 $ 355,220 $ ( 288,765 ) $ 66,481 Stock-based compensation - - 993 - 993 Sale of common stock, net of offering costs 54,414 - 770 - 770 Issuance of common stock from exercise of stock options 133 - 1 - 1 Net loss - - - ( 11,037 ) ( 11,037 ) Balance, March 31, 2023 25,729,370 $ 26 $ 356,984 $ ( 299,802 ) $ 57,208 See accompanying notes to the condensed consolidated financial statements. 5 Actinium Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (amounts in thousands) For the Three Months Ended March 31, 2024 2023 Cash Flows Used In Operating Activities: Net loss $ ( 8,670 ) $ ( 11,037 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense 1,378 993 Depreciation & amortization expenses 216 182 Changes in operating assets and liabilities: Prepaid expenses and other current assets 271 ( 1,989 ) Accounts payable and accrued expenses ( 440 ) ( 2,770 ) Operating lease right-of-use assets - ( 336 ) Operating lease liabilities ( 129 ) ( 120 ) Net Cash Used In Operating Activities ( 7,374 ) ( 15,077 ) Cash Flows Used In Investing Activities: Purchase of property and equipment ( 11 ) ( 76 ) Net Cash Used In Investing Activities ( 11 ) ( 76 ) Cash Flows Provided By Financing Activities: Payments on finance leases ( 2 ) ( 1 ) Sales of shares of common stock, net of costs 14,695 770 Proceeds from the exercise of stock options 75 1 Net Cash Provided By Financing Activities 14,768 770 Net

financial statements

financial statements. 6 Actinium Pharmaceuticals, Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) Note 1 - Description of Business and Summary of Significant Accounting Policies Nature of Business - Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing ARCs and other targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet medical needs. Basis of Presentation - Unaudited Interim Financial Information - The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the "SEC") with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's annual report on Form 10-K for the year ended December 31, 2023. Principles of Consolidation - The basis of consolidation is unchanged from the disclosure in the Company's Notes to the Consolidated Financial Statements section in its Report on Form 10-K for the year ended December 31, 2023. The unaudited condensed consolidated financial statements include the Company's accounts an

View Full Filing

View this 10-Q filing on SEC EDGAR